Piero Iamartino Appointed as Executive Director of the EIPG

Piero Iamartino, a long-standing leader within EIPG and former President of the association, has been appointed Executive Director effective 1 October 2025. With more than two decades dedicated to advancing the role of industrial pharmacists in Europe, he will now guide the implementation of EIPG’s strategic plan and support the organisation in addressing the technological and regulatory challenges shaping the future of the pharmaceutical sector.

"E.I.P.G. is a European association representing the national, professional organizations of pharmacists
employed in the pharmaceutical or allied industries of the Member States of the European Union,
the European Economic Area, or European countries having a mutual recognition agreement
with the European Union on compliance control of regulated medicines."

Read More

Presentations

Our media library contains an extensive collection of presentations by EIPG Bureau members or delegates, and presentations made at Scientific Symposia.
Read More
Read More

Position Papers

EIPG issues comments and feedback in response to consultation documents and white papers released by the European Medicines Agency and the European Commission.
Read More
Read More

Education

EIPG’s initiatives dedicated to industrial pharmacist education, including the EU-funded projects MOGLYNET, PHAR-IN and PHARMINE.
Read More
Read More

Members’ Area

Member organisations can sign in here to get even more information regarding EIPG’s projects and works.
Read More

Consultation open on the revision of GMP’s Chapter 1

Comments on the draft revision of Chapter 1 of the Good Manufacturing Practices must be submitted by 3 December 2025. The revision aims to update this fundamental text in light of the more recent advancements in pharmaceutical manufacturing, so to better ensure the ef-fectiveness and safety of medicinal products. The EIPG will liaise with member associations to submit a joint response to the draft text.
Read More

The EU Commission’s Study on the deployment of AI in healthcare

The DG Santé published in August 2025 a very detailed study on issues to be solved to ensure the swift implementation of artificial intelligence in healthcare. The study provides a thorough analyses of the current deployment of AI systems from technical, clinical, regulatory and societal perspectives, offering suggestions on how to address open issues
Read More

Latest EMA’s updates on the use of RWE in regulatory decision-making

The third annual report on the integration of real-world evidence (RWE) into regulatory decision-making shows a marked increase in the number of RWE studies conducted by the three pathways for generating RWE, the European consortium DARWIN EU, the framework contract (FWC), and in-house EMA studies. The PRAC Committee gave rise to the higher number of requests in the monitored period
Read More

Steps towards the new Pharma package and the EU Startup and Scaleup Strategy

In recent weeks, important steps have been taken towards the final adoption of the new European General Pharmaceutical Legislation, with the adoption of the Council’s position preliminar to the Trilogue discussions. The Commission also presented its new strategy to support European startups and scaleups, which are fundamental to improving innovation and European competitiveness
Read More

EU Life Sciences Strategy, comments to the call for evidence

The call for evidence closed on 17 April, and the proposal of the draft EU Life Sciences Strategy is expected by Q2 2025. It should encompass all the different industrial sectors in which life sciences play a central role for R&D and competitiveness, including pharmaceuticals, biotech and medtech
Read More